In:
Immunotherapy, Future Medicine Ltd, Vol. 15, No. 6 ( 2023-04), p. 397-400
Abstract:
Tweetable abstract Discontinuation of therapy for high-grade immune-related adverse events might not be detrimental to outcomes in renal cell carcinoma patients. We need translational studies to identify the optimal time of immune activation and provide guidance on therapy discontinuation.
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2023-0010
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2023
Bookmarklink